Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Paris Cedex 19, France Clinical Trials

A listing of Paris Cedex 19, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (1484) clinical trials

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every 4 weeks. Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for ...

Phase

0.0 miles

Learn More »

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Inclusion of MDS with IPSS low or int-1 and hemoglobin < 10/dL. Study drug: Darbepoetin alfa (Aranesp) 500 microg every two weeks subcutaneously during 12 weeks, combined to filgrastim 300 microg twice weekly for an additional 12 weeks in non responders. Response will be evaluated at 12 weeks. Patients with ...

Phase

0.0 miles

Learn More »

Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone

In open pilot studies, it has been suggested that bisphosphonates may alleviate bone pain and help decrease the surface of osteolytic lesion in patients with fibrous dysplasia of bone (FD). So, in this randomized placebo controlled trial, we test the hypothesis that the bisphosphonate risedronate reduces bone pain in patients ...

Phase

0.0 miles

Learn More »

Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease

The primary objective is to evaluate cardiac left ventricular mass (measured with echocardiography by unique investigator) in females over 15 years of age affected with Fabry disease receiving 70 mg of agalsidase beta every other week, as compared with an untreated controlled group matched for gender and age. The secondary ...

Phase

0.0 miles

Learn More »

A Prospective Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes

Methodology Data on patients with MDS will be collected prospectively at diagnosis and at 6-months intervals after diagnosis. The data will be gathered by seventeen (or more) countries that are represented within the LeukemiaNet MDS Working Party and will be combined in one central European Database. Data analyses will be ...

Phase N/A

0.0 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase

0.0 miles

Learn More »

Clofarabine Cytarabine and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia

OBJECTIVES: Primary - To determine the optimum dose of clofarabine in combination with cytarabine and idarubicin in patients with previously untreated intermediate- and high-risk acute myeloid leukemia or high-risk myelodysplasia. (Phase I) - To determine the safety and tolerance of this regimen in order to determine the recommended phase II ...

Phase

0.0 miles

Learn More »

Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2

We designed an open randomized study to evaluate the interest of maintenance treatment with interleukin-2 by randomizing the patients being not allogeneic transplanted in complete remission after induction and consolidation chemotherapy concerning the event free survival. A total of 580 patients will be accrued over 7 years. Treatment consists in ...

Phase

0.0 miles

Learn More »

National Gilles De La Tourette Study Group

Tourette syndrome is rare. In France, about 3000 patients have a severe form of the disease. The aim of this study is to collect clinical characteristics in 200 patients with Tourette syndrome.

Phase N/A

0.0 miles

Learn More »

Clinical Molecular and Metabolic Characteristics of Parkinson's Disease (PD) Patients With Parkin Mutation

Parkinson's disease is a frequent neurodegenerative disorder. Genetic forms of the disease have been recently identified. The monogenic form due to parkin mutation is responsible for many familial cases and sporadic forms. However, the relationship between the mutation and the genotype of patients is not fully established. The aim of ...

Phase N/A

0.0 miles

Learn More »